News from the FDA/CDC

FDA: PrEP indication updated to include adolescents at risk of HIV infection


 

  • inconsistent or no condom use.
  • diagnosis of sexually transmitted infections.
  • exchange of sex for commodities (such as money, food, shelter, or drugs).
  • use of illicit drugs or alcohol dependence.
  • incarceration.
  • partner(s) of unknown HIV-1 status with any of the factors listed above.

Dosage and administration

2.1 Testing prior to initiation of Truvada for treatment of HIV-1 infection or for HIV-1 PrEP

Prior to or when initiating Truvada, test patients for hepatitis B virus infection [see Warnings and Precautions (5.1)].

Prior to initiation and during use of Truvada, on a clinically appropriate schedule, assess serum creatinine, estimated creatinine clearance, urine glucose and urine protein in all patients. In patients with chronic kidney disease, also assess serum phosphorus

Pages

Recommended Reading

Time to HIV rebound in infants off ART linked to birth health
MDedge Family Medicine
MDedge Daily News: Can androgen therapy improve male frailty?
MDedge Family Medicine
Medical marijuana’s ‘Catch-22’: Federal limits on research hinder patients’ relief
MDedge Family Medicine
Comorbidity occurs earlier and more commonly with HIV infection
MDedge Family Medicine
Antiretroviral choice for pregnant women with HIV does not appear to impact birth outcomes
MDedge Family Medicine
HIV infection linked to higher risk of non-melanoma skin cancer
MDedge Family Medicine
Most HIV patients need treatment for acute HCV
MDedge Family Medicine
Emotional regulation training lowers risk of adolescents having sex
MDedge Family Medicine
FDA seeks comments on pediatric HIV product development
MDedge Family Medicine
FDA approves epoetin alfa biosimilar to treat anemia
MDedge Family Medicine